Vasily J. Assikis

986 total citations
21 papers, 728 citations indexed

About

Vasily J. Assikis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Vasily J. Assikis has authored 21 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Vasily J. Assikis's work include Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Vasily J. Assikis is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Vasily J. Assikis collaborates with scholars based in United States, Sweden and Belgium. Vasily J. Assikis's co-authors include Adam G. Baseman, Haiyen E. Zhau, Leland W.K. Chung, Peter A.S. Johnstone, David A. Kooby, Jonathan W. Simons, Aman U. Buzdar, Peter A.S. Johnstone, Michael Goodman and Kevin C. Ward and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Vasily J. Assikis

21 papers receiving 707 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vasily J. Assikis United States 12 328 233 216 205 145 21 728
Stefano Sioletic Italy 14 282 0.9× 214 0.9× 241 1.1× 99 0.5× 110 0.8× 27 719
Joana Vieira Portugal 14 293 0.9× 344 1.5× 220 1.0× 85 0.4× 134 0.9× 39 701
W. M. Linehan United States 7 359 1.1× 243 1.0× 125 0.6× 150 0.7× 229 1.6× 12 690
Kilian Mellon United Kingdom 12 347 1.1× 254 1.1× 340 1.6× 363 1.8× 164 1.1× 16 839
Attila Szendrői Hungary 19 293 0.9× 314 1.3× 168 0.8× 383 1.9× 207 1.4× 48 843
K. W. Schmid Germany 17 134 0.4× 219 0.9× 159 0.7× 205 1.0× 135 0.9× 37 816
Takaomi Koga Japan 17 323 1.0× 327 1.4× 311 1.4× 88 0.4× 123 0.8× 38 819
Lucia Nappi Canada 13 240 0.7× 405 1.7× 153 0.7× 191 0.9× 186 1.3× 78 734
Masatoshi Moriyama Japan 13 328 1.0× 233 1.0× 152 0.7× 191 0.9× 169 1.2× 47 590
Kunio Araki Japan 15 198 0.6× 227 1.0× 215 1.0× 101 0.5× 139 1.0× 36 599

Countries citing papers authored by Vasily J. Assikis

Since Specialization
Citations

This map shows the geographic impact of Vasily J. Assikis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vasily J. Assikis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vasily J. Assikis more than expected).

Fields of papers citing papers by Vasily J. Assikis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vasily J. Assikis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vasily J. Assikis. The network helps show where Vasily J. Assikis may publish in the future.

Co-authorship network of co-authors of Vasily J. Assikis

This figure shows the co-authorship network connecting the top 25 collaborators of Vasily J. Assikis. A scholar is included among the top collaborators of Vasily J. Assikis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vasily J. Assikis. Vasily J. Assikis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Flaig, Thomas W., Jonathan E. Rosenberg, Christopher Hoimes, et al.. (2023). Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.. Journal of Clinical Oncology. 41(16_suppl). 4595–4595. 9 indexed citations
2.
Rao, Arpit, David Morris, Vasily J. Assikis, et al.. (2021). Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study.. Journal of Clinical Oncology. 39(6_suppl). 79–79. 7 indexed citations
3.
Denmeade, Samuel R., Hao Wang, Wei Fu, et al.. (2020). TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(15_suppl). 5517–5517. 2 indexed citations
4.
Overton, Lindsay, Christopher L. Corless, Manish Agrawal, et al.. (2014). Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting.. Journal of Clinical Oncology. 32(15_suppl). 11028–11028. 1 indexed citations
5.
Armstrong, Andrew J., Michael Häggman, Walter M. Stadler, et al.. (2013). Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 19(24). 6891–6901. 46 indexed citations
6.
Armstrong, Andrew J., Michael Häggman, Walter M. Stadler, et al.. (2011). Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups.. Journal of Clinical Oncology. 29(7_suppl). 126–126. 4 indexed citations
7.
Пили, Роберто, Michael Häggman, Walter M. Stadler, et al.. (2010). A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 28(15_suppl). 4510–4510. 16 indexed citations
8.
Johnstone, Peter A.S., Robert H. Riffenburgh, Peter J. Rossi, et al.. (2007). Applying Population Dynamics Modeling to Patients With Lymph Node Positive Prostate Cancer. The Journal of Urology. 178(5). 1952–1956. 3 indexed citations
9.
Johnstone, Peter A.S., Kevin C. Ward, Michael Goodman, Vasily J. Assikis, & John A. Petros. (2006). Radical prostatectomy for clinical T4 prostate cancer. Cancer. 106(12). 2603–2609. 59 indexed citations
10.
Rasco, Drew, Vasily J. Assikis, & Fray F. Marshall. (2006). Integrating Metastasectomy in the Management of Advanced Urological Malignancies—Where are we in 2005?. The Journal of Urology. 176(5). 1921–1926. 14 indexed citations
11.
Chung, Leland W.K., Adam G. Baseman, Vasily J. Assikis, & Haiyen E. Zhau. (2005). MOLECULAR INSIGHTS INTO PROSTATE CANCER PROGRESSION: THE MISSING LINK OF TUMOR MICROENVIRONMENT. The Journal of Urology. 173(1). 10–20. 278 indexed citations
12.
Assikis, Vasily J. & Jonathan W. Simons. (2004). Novel therapeutic strategies for androgen-independent prostate cancer: An update. Seminars in Oncology. 31(2 Suppl 4). 26–32. 34 indexed citations
13.
Assikis, Vasily J., Kim‐Anh Do, Sijin Wen, et al.. (2004). Clinical and Biomarker Correlates of Androgen-Independent, Locally Aggressive Prostate Cancer with Limited Metastatic Potential. Clinical Cancer Research. 10(20). 6770–6778. 33 indexed citations
14.
Assikis, Vasily J., et al.. (2004). Primary retroperitoneal teratomas: A review of the literature. Journal of Surgical Oncology. 86(2). 107–113. 153 indexed citations
15.
Logothetis, Christopher J., Vasily J. Assikis, & Jose E. Sarriera. (2003). Diagnosis, Treatment, and Prevention of Nephrotoxicity of Cancer Therapeutic Agents. 2 indexed citations
16.
Daliani, Danai, Vasily J. Assikis, Shi‐Ming Tu, et al.. (2003). Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen‐independent prostate carcinoma. Cancer. 97(3). 561–567. 21 indexed citations
17.
Assikis, Vasily J., Aman U. Buzdar, Ying Yang, et al.. (2003). A Phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma. Cancer. 97(11). 2716–2723. 11 indexed citations
18.
Logothetis, Christopher J., Vasily J. Assikis, & Jose E. Sarriera. (2003). Complications Resulting from Primary Cancer Progression. 1 indexed citations
19.
Assikis, Vasily J. & Aman U. Buzdar. (2002). Recent advances in aromatase inhibitor therapy for breast cancer. Seminars in Oncology. 29(3 Suppl 11). 120–128. 13 indexed citations
20.
Assikis, Vasily J. & Aman U. Buzdar. (2002). Recent advances in aromatase inhibitor therapy for breast cancer. Seminars in Oncology. 29(3). 120–128. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefano Sioletic Breakdown of academic impact, for papers by Joana Vieira Breakdown of academic impact, for papers by W. M. Linehan Breakdown of academic impact, for papers by Kilian Mellon Breakdown of academic impact, for papers by Attila Szendrői Breakdown of academic impact, for papers by K. W. Schmid Breakdown of academic impact, for papers by Takaomi Koga Breakdown of academic impact, for papers by Lucia Nappi Breakdown of academic impact, for papers by Masatoshi Moriyama Breakdown of academic impact, for papers by Kunio Araki
Rankless by CCL
2026